Solstice Oncology
PrivateLast Round
Series A
Sep 9, 2026
Total Funding Raised
$225M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Solstice Oncology operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A round in September 2026.
Solstice Oncology is a clinical-stage immuno-oncology company that develops therapeutic treatments for cancer in the neoadjuvant setting.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Solstice Oncology Comparables
Compare Solstice Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoC4, Inc. | 78% | |
| Evida Biosciences | 77% | |
| Treos Bio | 75% |
For institutional investors. Book with your work email.
Solstice Oncology Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Solstice Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A |
| Forbion | Series A |
| Canaan Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 9, 2026
$225M round led by RA Capital Management.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 9, 2026
Solstice Oncology receives $225M Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors, on Sep 9th '26 to advance Porustobart, a neoadjuvant immuno-oncology therapy.
For institutional investors. Book with your work email.
Solstice Oncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Solstice Oncology's valuation, stock price, and market status.
Is Solstice Oncology a public or private company?
Solstice Oncology is a private company.
What is the current stock price of Solstice Oncology?
Solstice Oncology is a private company, so its shares have no public market price. Caplight tracks Solstice Oncology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Solstice Oncology worth (valuation)?
Valuation information for Solstice Oncology is not publicly available.
Can I buy Solstice Oncology stock?
Solstice Oncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Solstice Oncology's last funding round?
Solstice Oncology's most recent funding round was Series A on September 9, 2026.
Who are the main investors in Solstice Oncology?
Key investors in Solstice Oncology include RA Capital Management.
Will Solstice Oncology IPO soon?
No public IPO plans have been announced for Solstice Oncology.
How can I track Solstice Oncology secondary market activity?
Caplight tracks bids, offers, and trades in Solstice Oncology's shares on secondary markets.